TOP > 外国特許検索 > THERAPEUTIC AGENT FOR SARCOPENIA AND METABOLIC DISEASES

THERAPEUTIC AGENT FOR SARCOPENIA AND METABOLIC DISEASES NEW

外国特許コード F170009012
整理番号 (S2015-2004-N0)
掲載日 2017年3月29日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP076627
国際公開番号 WO 2017043630
国際出願日 平成28年9月9日(2016.9.9)
国際公開日 平成29年3月16日(2017.3.16)
優先権データ
  • 特願2015-179698 (2015.9.11) JP
発明の名称 (英語) THERAPEUTIC AGENT FOR SARCOPENIA AND METABOLIC DISEASES NEW
発明の概要(英語) The present invention provides a therapeutic agent for sarcopenia or metabolic diseases, which contains a mu-crystalline (CRYM)-inhibiting substance as an active ingredient. The inhibiting substance is selected from the group consisting of an antisense nucleic acid for CRYM, an RNAi-induced nucleic acid, a ribozyme or an expression vector therefore, an antagonist antibody, and a low-molecular-weight compound capable of inhibiting the activity of CRYM.
特許請求の範囲(英語) [claim1]
1. Mu chestnut star phosphorus (CRYM) containing the deterrent as the active ingredient, the muscular strength decrease symptom which becomes ([sarukopenia]) or the remedy of the metabolism characteristic disease.
[claim2]
2. Anti sense nuclear acid and the RNAi inductive nuclear acid the CRYM deterrent for CRYM, [ribozaimu] or it is something which is chosen from those manifestation vectors, and the group which consists of the antagonist antibody, and the low molecular weight compound which obstructs the activity of CRYM, in claim 1 the remedy of statement.
[claim3]
3. The muscular strength decrease symptom is field occurrence [sarukopenia], body ctive [sarukopenia], diseased characteristic [sarukopenia] or nutrition characteristic [sarukopenia], is the metabolism characteristic disease where the metabolism characteristic disease is annexed to aforementioned [sarukopenia], in claim 1 or 2 the remedy of statement.
[claim4]
4. The metabolism characteristic disease sugar metabolic error or lipid either of the claim 1-3 which is metabolic error in 1 sections the remedy of statement.
[claim5]
5. The CRYM deterrent of the effective quantity the process which is prescribed to the object which needs that is included, the muscular strength decrease symptom ([sarukopenia]) or remedy method of the metabolism characteristic disease.
[claim6]
6. Anti sense nuclear acid and the RNAi inductive nuclear acid the CRYM deterrent for CRYM, [ribozaimu] or it is something which is chosen from those manifestation vectors, and the group which consists of the antagonist antibody, and the low molecular weight compound which obstructs the activity of CRYM, in claim 5 remedy method of statement.
[claim7]
7. It is chosen from the group where the muscular strength decrease symptom consists of field occurrence [sarukopenia], body ctive [sarukopenia], diseased characteristic [sarukopenia] and nutrition characteristic [sarukopenia] and aforementioned [sarukopenia] which accompanies the metabolism characteristic disease, in claim 5 or 6 remedy method of statement.
[claim8]
8. The metabolism characteristic disease sugar metabolic error or lipid either of the claim 5-7 which is metabolic error in 1 sections remedy method of statement.
[claim9]
9. Either of the claim 1-4 in 1 sections the muscular strength decrease symptom of statement ([sarukopenia]) or, use of the CRYM deterrent in order to produce the remedy of the metabolism characteristic disease.
[claim10]
10. The muscular strength decrease symptom ([sarukopenia]) or, the CRYM deterrent in order to use for the remedy of the metabolism characteristic disease.
[claim11]
11. The muscular strength decrease symptom ([sarukopenia]) or anti sense nuclear acid and the RNAi inductive nuclear acid for, CRYM in order to use for the remedy of the metabolism characteristic disease, [ribozaimu] or from those manifestation vectors, and the group which consists of the antagonist antibody, and the low molecular weight compound which obstructs the activity of CRYM the CRYM deterrent which is chosen.
[claim12]
12. The muscular strength decrease symptom is field occurrence [sarukopenia], body ctive [sarukopenia], diseased characteristic [sarukopenia] or nutrition characteristic [sarukopenia], is the metabolism characteristic disease where the metabolism characteristic disease is annexed to aforementioned [sarukopenia], in claim 10 or 11 the CRYM deterrent of statement.
[claim13]
13. The metabolism characteristic disease sugar metabolic error or lipid either of the claim 10-12 which is metabolic error in 1 sections the CRYM deterrent of statement.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NAGASAKI UNIVERSITY
  • 発明者(英語)
  • ONO YUSUKE
国際特許分類(IPC)
指定国 (WO201743630)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
上記の特許・技術に関心のある方は、下記問い合わせ先にご相談下さい。

PAGE TOP

close
close
close
close
close
close